Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Common Equity: 2015-2024

Historic Common Equity for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $872.0 million.

  • Intellia Therapeutics' Common Equity fell 22.25% to $748.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $748.4 million, marking a year-over-year decrease of 22.25%. This contributed to the annual value of $872.0 million for FY2024, which is 16.97% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Common Equity of $872.0 million as of FY2024, which was down 16.97% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Common Equity ranged from a high of $1.2 billion in FY2022 and a low of $527.1 million during FY2020.
  • Moreover, its 3-year median value for Common Equity was $1.1 billion (2023), whereas its average is $1.1 billion.
  • As far as peak fluctuations go, Intellia Therapeutics' Common Equity skyrocketed by 97.36% in 2021, and later decreased by 16.97% in 2024.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Common Equity stood at $527.1 million in 2020, then soared by 97.36% to $1.0 billion in 2021, then grew by 18.78% to $1.2 billion in 2022, then decreased by 15.01% to $1.1 billion in 2023, then declined by 16.97% to $872.0 million in 2024.